



Cite this: *Chem. Commun.*, 2015, 51, 4507

Received 12th January 2015,
Accepted 9th February 2015

DOI: 10.1039/c5cc00268k

www.rsc.org/chemcomm

Rh(II)-catalyzed cycloadditions of 1-tosyl 1,2,3-triazoles with 2H-azirines: switchable reactivity of Rh-azavinylcarbene as [2C]- or aza-[3C]-synthon†

Yuanhao Wang,^a Xiaoqiang Lei^a and Yefeng Tang^{*abc}

The Rh(II)-catalyzed formal [3+2] and [3+3] cycloadditions of 1-tosyl 1,2,3-triazoles with 2H-azirines have been developed, which enable the efficient synthesis of polysubstituted 3-aminopyrroles and 1,2-dihydropyrazines, respectively. The reported [3+2] cycloaddition represents the first application of 1-sulfonyl 1,2,3-triazole as a [2C]-component in relevant cycloaddition reactions.

Readily generated from 1-sulfonyl 1,2,3-triazole through denitrogenation upon treatment with an Rh(II)-catalyst, Rh-azavinylcarbene (Rh-AVC) has evolved into a versatile reactive intermediate in organic synthesis over the past several years.¹ On one hand, it displays typical reactivity of metallocarbene derived from diazo compound,² and has been employed as [1C]-synthon in various reactions including cyclopropanation,³ X-H (X = C, O or N) insertion,⁴ ylide formation and rearrangement⁵ and others⁶ (eqn (1), Fig. 1a). On the other hand, owing to its dipolar nature, it could also function as aza-[3C]-synthon in a wide range of cycloadditions, such as [3+2],⁷ [3+3],⁸ [4+3]⁹ and other multi-component cycloadditions (eqn (2), Fig. 1a).¹⁰ Despite such progress, the utilization of Rh-AVC as [2C]-synthon in cycloaddition reactions has never been explored so far (eqn (3), Fig. 1a).

2H-Azirines represent a class of highly strained three-membered cyclic imines that have been employed as versatile precursors for the synthesis of various heterocycles.¹¹ For example, Park and co-workers recently reported an interesting formal [3+3] cycloaddition of vinyl carbenoids with 2H-azirines, which resulted in the formation of polysubstituted pyridines.¹²

Inspired by this seminal work, we envisioned that it was feasible to unite the two 1,3-dipolarophiles Rh-AVC and 2H-azirine in a single transformation to realize a formal aza-[3+3] cycloaddition, which would afford an efficient method for the synthesis of 1,2-dihydropyrazines (eqn (5), Fig. 1b) as well as related heterocycles (e.g. pyrazine). As a part of our continuing interest in the development of novel Rh-AVC promoted transformations,^{9a,13} we report herein the successful implementation of this design, which leads to the development of unprecedented Rh(II)-catalyzed formal [3+2] and [3+3] cycloadditions of 1,2,3-triazoles with 2H-azirines (Fig. 1b). Of note, the putative Rh-AVC intermediate in the [3+2] cycloaddition serves as [2C]- instead of [1C]- or aza-[3C]-synthon.¹⁴

The readily accessible triazole **1a** and 3-phenyl-2H-azirine **2a** were employed as substrates in the initial study.¹⁵ Thus, **1a** and **2a** were treated with 1.5 mol% Rh₂(OAc)₄ in 1,2-DCE at 140 °C for 4 h, which resulted in the formation of a product in 48% yield. Careful analysis of its spectroscopic data suggested that it was not the expected [3+3] adduct, but 3-amino-pyrrole derivative **3a** (entry 1, Table 1). The structural assignment of **3a** was




Fig. 1 (a) The graphic illustration of versatile reactivities of Rh-AVC; (b) the cycloaddition developed in current work.

^a The Comprehensive AIDS Research Center and The Department of Pharmacology & Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing 100084, P. R. China. E-mail: yefengtang@tsinghua.edu.cn; Tel: +86 10 62798236

^b Collaborative Innovation Center for Biotherapy, Tsinghua University, Beijing 100084, China

^c Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, P. R. China

† Electronic supplementary information (ESI) available: Detailed experimental procedures and spectroscopic data of all new compounds. CCDC 1032468 and 1032469. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5cc00268k

Table 1 Condition screening of cycloaddition of **1a** with **2a**^a

Entry	Cat.	Solvent	Other conditions	Yield of 3a ^b (%)
1	Rh ₂ (OAc) ₄	1,2-DCE	140 °C, 4 h	48
2	Rh ₂ (OAc) ₄	1,2-DCE	120 °C, 10 h	38
3	Rh ₂ (OAc) ₄	1,2-DCE	160 °C, 1 h	57
4	Rh ₂ (oct) ₄	1,2-DCE	160 °C, 1 h	45
5	Rh ₂ (S-ptad) ₄	1,2-DCE	160 °C, 1 h	Trace
6	Rh ₂ (S-dosp) ₄	1,2-DCE	160 °C, 1 h	Trace
7	Rh ₂ (esp) ₂	1,2-DCE	160 °C, 1 h	81
8	Rh ₂ (esp) ₂	1,2-DCE	160 °C, 1 h, 4 Å MS	62
9	Rh ₂ (esp) ₂	1,2-DCE	160 °C, MW, 15 min	50

^a Reaction conditions: **1a** (0.30 mmol), **2a** (0.6 mmol) and Rh(II)-cat. (0.0045 mmol) in 1,2-DCE (0.8 mL). ^b Isolated yield. DCE = dichloroethane, oct = octanoate, (S)-ptad = *N*-phthaloyl-(S)-adamantylglycine, (S)-dosp = 4-(dodecyl-phenyl)sulfonyl-(2S)-proline, esp = *a,a,a',a'*-tetramethyl-1,3-benzenedipropionate, MS = molecular sieves, MW = microwave.

further confirmed by the X-ray crystallographic study of its derivative **3a'** (structure not shown, for details, see the ESI†).¹⁶

The initial discovery deserves further investigation, since it represents a formal [3+2] cycloaddition, wherein the triazole partner served as [2C]- instead of the proposed *aza*-[3C]-component. Moreover, the resulting 3-amino-pyrrole derivative represents a valuable structural motif distributed in natural products and bioactive molecules.¹⁷ To improve the efficiency of the transformation, we conducted a systematic condition screening (Table 1). It was shown that lower temperature was detrimental to the reaction (entry 2), while higher temperature afforded **3a** in improved yield (entry 3). The Rh(II)-catalyst also had a notable influence on the reaction. While Rh₂(oct)₄ displayed reactivity similar to Rh₂(OAc)₄, the sterically hindered Rh₂(S-ptad)₄ and Rh₂(S-dosp)₄ failed to yield the desired product (entries 4–6). Gratifyingly, Rh₂(esp)₂, a dirhodium complex with tethered carboxylate ligands,¹⁸ exhibited superior reactivity by giving **3a** in 81% yield (entry 7). We also attempted to perform the reaction in the presence of 4 Å MS or upon microwave irradiation, however, both of them resulted in inferior yields (entries 8 and 9).

The generality of the cycloaddition was then evaluated with various monosubstituted 2*H*-azirines (Table 2). First of all, an array of 3-aryl-2*H*-azirines were examined with **1a** as the reaction partner. Gratifyingly, all of the substrates bearing either electron withdrawing (4-Br, 2-Cl, 4-F or 4-NO₂) or donating (4-Me or 4-MeO) substituents gave the corresponding products (**3a–g**) in good yields. The 2-naphthyl- or 3-indol-derived 2*H*-azirines were also tolerated well. Moreover, the reaction could extend to 3-alkyl-2*H*-azirines, as shown in the cases leading to **3j** and **3k**. Besides **1a**, a wide range of 1-tosyl-4-aryl-1,2,3-triazoles were also examined with **2a** as a reaction partner. All of the reactions gave the desired products (**3l–p**) in satisfying yields, showing little electronic effect regarding the substituents on aromatic rings.

Furthermore, we explored 2,3-disubstituted substrates in the reactions. Interestingly, we found that when 2,3-diphenyl-2*H*-azirine **4a** was subjected to the optimized conditions, a mixture of tetrasubstituted 3-amino-pyrrole **5a** and 2,3,5-trisubstituted

Table 2 Scope of Rh(II)-catalyzed cycloadditions of 1-tosyl 1,2,3-triazoles with monosubstituted 2*H*-azirines^{a,b}

3a : 81%	3b : 65%	3c : 57%
3d : 79%	3e : 64%	3f : 74%
3g : 70%	3h : 85%	3i : 72%
3j : 65%	3k : 72%	3l : 71%
3m : 70%	3n : 72%	3o : 67%
3p : 70%		

^a Reaction conditions: **1a** (0.30 mmol), **2** (0.60 mmol) and the Rh(II)-catalyst (0.0045 mmol) in 1,2-DCE (0.8 mL). ^b Isolated yield.

1,2-dihydropyrazine **6a** was obtained in 36% and 48% yields, respectively (entry 1, Table 3). The structure of **6a** was confirmed by the X-ray crystallographic study.¹⁶ These results showed that the introduction of the aromatic substituent on the C-2 position of 2*H*-azirine largely inverted its reactivity. Although the efficiency of the reaction was excellent, the poor selectivity discounted its synthetic utility. Thus, we sought to improve the reaction with the further condition optimization. Fortunately, we found that by simply changing the solvent from 1,2-DCE to toluene notably increased the selectivity of [3+3] vs [3+2] from 1.3:1 to 6.3:1, with **6a** obtained in 82% yield (condition B, entry 2).¹⁹ Furthermore, the use of sub-stoichiometric amounts of ClCH₂COOH in the reaction could invert the selectivity of the reaction.²⁰ As a result, **5a** was isolated in 86% yield, along with only a small amount of **6a** (11%) (condition C, entry 3).

Table 3 Condition screening of cycloaddition of **1a** with **4a**^a

Entry	Conditions	Yield of products ^b
1	A: Rh ₂ (esp) ₂ (1.5 mol%), 1,2-DCE, 160 °C, 1 h	5a : 36%; 6a : 48%
2	B: Rh ₂ (esp) ₂ (1.5 mol%), toluene, 160 °C, 1 h	5a : 13%; 6a : 82%
3	C: Rh ₂ (esp) ₂ (1.5 mol%), ClCH ₂ CO ₂ H (50 mol%), 1,2-DCE, 160 °C, 0.5 h	5a : 86%; 6a : 11%


^a Reaction conditions: **1a** (0.30 mmol), **4a** (0.60 mmol) and the Rh(II)-catalyst (0.0045 mmol) in the solvent (0.8 mL). ^b Isolated yield.

The above discovery was encouraging, since it enabled the divergent synthesis of two different heterocycles from common precursors simply by tuning reaction conditions. To test its generality, several other symmetric 2,3-diaryl-2*H*-azirines (**4b–d**) were evaluated under the dual condition systems (Table 4). To our delight, all of them afforded the expected [3+3] adducts (**6b–d**) under condition B and [3+2] adducts (**5b–d**) under condition C (entries 2–4) with excellent yields and good selectivity. Besides, a variety of 2-alkyl-3-Ph-2*H*-azirines (**4e–h**) were also tested. Gratifyingly, all of them exhibited propensity similar to the 2,3-diaryl-2*H*-azirines, affording satisfying results (entries 5–8).

To further explore the substituent effect of 2*H*-azirines on the reaction outcomes, an array of 2-aryl-3-alkyl-2*H*-azirines (**7a–g**) were evaluated (Table 5). Unlike the above-mentioned 2,3-disubstituted 2*H*-azirines, this type of substrate only yielded the [3+3] adducts (**8a–g**) in good yields under condition A. Comparable results were obtained with condition B employed, however, the usage of condition C failed to invert the selectivity of the reactions. In sharp contrast, when several 2-carboxylate-3-aryl/alkyl-2*H*-azirines **9a–d** were employed, they displayed propensity close to monosubstituted substrates, affording [3+2] adducts **10a–d** in excellent yields (Table 5).

All the above-mentioned outcomes suggested that the structural feature of the 2*H*-azirine partner plays an important role in determining the reaction pathways. Given that, the plausible mechanism of the titled reactions is depicted in Scheme 1. The nucleophilic attack of 2*H*-azirine on Rh-AVC **A** leads to azirinium ylide **B**. At this point, there are several possibilities for **B** to evolve into the final products. On one hand, it could convert into **C** *via* resonant equilibrium, which then undergoes ring expansion to

Table 5 Scope of Rh(II)-catalyzed cycloadditions of **1a** with 2-aryl-3-alkyl-2*H*-azirines and 2-carboxylate-3-aryl/alkyl-2*H*-azirines^{a,b}




^a Condition A: **1a** (0.30 mmol), **8** or **10** (0.60 mmol) and the Rh(II)-catalyst (0.0045 mmol) in 1,2-DCE (0.8 mL) at 160 °C for 1 h. ^b Isolated yield.

Table 4 Scope of Rh(II)-catalyzed cycloadditions of **1a** with 2,3-diaryl-2*H*-azirines and 2-alkyl-3-Ph-2*H*-azirines^a

Condition B		Condition C	
(R ₂ = aryl or alkyl; R ₃ = aryl)		(R ₂ = aryl or alkyl; R ₃ = aryl)	
Entry	2 <i>H</i> -Azirine	Condition B	Condition C
1			
2			
3			
4			
5			
6			
7			
8			

^a Condition B: **1a** (0.30 mmol), **4** (0.6 mmol) and Rh-catalyst (0.0045 mmol) in toluene (0.8 mL); condition C: **1a** (0.30 mmol), **4** (0.6 mmol), ClCH₂CO₂H (0.15 mmol) and the Rh-catalyst (0.0045 mmol) in 1,2-DCE (1.0 mL). ^b Isolated yield. ^c Obtained as a mixture of diastereoisomers (1 : 1).

generate the zwitterionic intermediate **D**. After proton transfer followed by isomerization, **D** could advance to the pyrrole product (path a). On the other hand, **B** could divert into carbocation **F** *via* cleavage of the C2–N2 bond. **F** then undergoes cyclization to give 1,2-dihydropyrazine (path b-1).²¹ Alternatively, **B** could also transform into 1,4-azatriene **G** which further evolves into the 1,2-dihydropyrazine product *via* 6π electrocyclic cyclization (path b-2). Notably, the above mechanistic considerations are in good agreement with the experimental results. For example, for 2*H*-azirines **2** and **9** (R₂ = H or CO₂Et), the formation of carbocation **F** is disfavored, and thus path b-1 is excluded. While path b-2 could be envisioned in this scenario,²² path a more readily takes place to afford the thermodynamically more stable pyrrole product. In contrast, for 2-aryl-3-alkyl-2*H*-azirines **7**, intermediate **B** prefers to advance to the more stable benzylic carbocation **F**, thus leading to [3+3] adducts *via* path b-1. For 2*H*-azirines **4**, both pathways may take place



Scheme 1 Proposed mechanism of Rh(II)-catalyzed cycloadditions of 1,2,3-triazoles with 2*H*-azirines.

concurrently due to the comparable stability of intermediates **F** and **C**.

In summary, the Rh(II)-catalyzed formal [3+2] and [3+3] cycloadditions of 1-tosyl 1,2,3-triazoles with 2*H*-azirines have been developed, which enable the efficient synthesis of poly-substituted 3-amino-pyrroles and 1,2-dihydropyrazines. The selectivity of the cycloadditions is mainly determined by the structural feature of 2*H*-azirine partners, and in some cases, could be controlled by tuning the reaction conditions. The reported [3+2] cycloaddition represents a proof-of-concept case that utilizes 1-sulfonyl 1,2,3-triazole as a [2C]-component in cycloaddition reactions, which may inspire the development of some other new transformations. Such efforts are undertaken in our lab and will be reported in due course.

We gratefully acknowledge the financial support from the NSFC (21102081, 21272133), the Beijing Natural Science Foundation (2132037) and the New Teachers' Fund for Doctor Stations, Ministry of Education (20110002120011).

Notes and references

- For leading reviews, see: (a) B. Chattopadhyay and V. Gevorgyan, *Angew. Chem., Int. Ed.*, 2012, **51**, 862; (b) A. V. Gulevich and V. Gevorgyan, *Angew. Chem., Int. Ed.*, 2013, **52**, 1371; (c) H. M. L. Davies and J. S. Alford, *Chem. Soc. Rev.*, 2014, **43**, 5151.
- For selected reviews, see: (a) H. M. L. Davies and R. E. J. Beckwith, *Chem. Rev.*, 2003, **103**, 2861; (b) H. Lebel, J. Marcoux, M. Carmela and A. B. Charette, *Chem. Rev.*, 2003, **103**, 977; (c) M. P. Doyle, R. Duffy, M. Ratnikov and L. Zhou, *Chem. Rev.*, 2010, **110**, 704.
- (a) S. Chuprakov, S. W. Kwok, L. Zhang, L. Lercher and V. V. Fokin, *J. Am. Chem. Soc.*, 2009, **131**, 18034; (b) N. Grimster, L. Zhang and V. V. Fokin, *J. Am. Chem. Soc.*, 2010, **132**, 2510; (c) M. Zibinsky and V. V. Fokin, *Org. Lett.*, 2011, **13**, 4870; (d) J. S. Alford and H. M. L. Davies, *Org. Lett.*, 2012, **14**, 6020.
- (a) S. Chuprakov, J. A. Malik, M. Zibinsky and V. V. Fokin, *J. Am. Chem. Soc.*, 2011, **133**, 10352; (b) T. Miura, T. Biyajima, T. Fujii and M. J. Murakami, *J. Am. Chem. Soc.*, 2012, **134**, 194; (c) T. Miura, T. Tanaka, T. Biyajima, A. Yada and M. Murakami, *Angew. Chem., Int. Ed.*, 2013, **52**, 3883; (d) S. Chuprakov, B. T. Worrell, N. Selander, R. K. Sit and V. V. Fokin, *J. Am. Chem. Soc.*, 2014, **136**, 195.
- (a) J. K. Fu, H. J. Shen, Y. Y. Chang, C. C. Li, J. X. Gong and Z. Yang, *Chem. – Eur. J.*, 2014, **20**, 12881; (b) A. Boyer, *Org. Lett.*, 2014, **16**, 1660.
- (a) Y. Funakoshi, M. Morimoto, T. Biyajima and M. Murakami, *J. Am. Chem. Soc.*, 2012, **134**, 17440; (b) N. Selander, B. T. Worrell, S. Chuprakov, S. Velaparthi and V. V. Fokin, *J. Am. Chem. Soc.*, 2012, **134**, 14670; (c) N. Selander, B. T. Worrell and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2012, **51**, 13054; (d) T. Miura, T. Tanaka, T. Biyajima, A. Yada and M. Murakami, *Angew. Chem., Int. Ed.*, 2013, **52**, 3883; (e) R. H. Liu, M. Zhang, G. Winston-McPherson and W. P. Tang, *Chem. Commun.*, 2013, **49**, 4376; (f) J. Yang, C. Zhu, X. Tang and M. Shi, *Angew. Chem., Int. Ed.*, 2014, **53**, 5142; (g) F. Medina, C. Besnard and J. Lacour, *Org. Lett.*, 2014, **16**, 3232; (h) Y. S. Zhang, X. Y. Tang and M. Shi, *Chem. Commun.*, 2014, **50**, 15971; (i) X. Y. Tang, Y. S. Zhang, L. He, Y. Wei and M. Shi, *Chem. Commun.*, 2015, **51**, 133.
- (a) T. Horneff, S. Chuprakov, N. Chernyak, V. Gevorgyan and V. V. Fokin, *J. Am. Chem. Soc.*, 2008, **130**, 14972; (b) T. Miura, M. Yamauchi and M. Murakami, *Chem. Commun.*, 2009, 1470; (c) B. Chattopadhyay and V. Gevorgyan, *Org. Lett.*, 2011, **13**, 3746; (d) T. Miura, K. Hiraga, T. Biyajima, T. Nakamuro and M. Murakami, *Org. Lett.*, 2013, **15**, 3298; (e) S. Chuprakov, S. W. Kwok and V. V. Fokin, *J. Am. Chem. Soc.*, 2013, **135**, 4652; (f) E. E. Schultz and R. Sarpong, *J. Am. Chem. Soc.*, 2013, **135**, 4696; (g) B. T. Parr, S. A. Green and H. M. J. Davies, *J. Am. Chem. Soc.*, 2013, **135**, 4716; (h) J. E. Spangler and H. M. L. Davies, *J. Am. Chem. Soc.*, 2013, **135**, 6802; (i) J. S. Alford, J. E. Spangler and H. M. L. Davies, *J. Am. Chem. Soc.*, 2013, **135**, 11712; (j) M. Zibinsky and V. V. Fokin, *Angew. Chem., Int. Ed.*, 2013, **52**, 1507; (k) T. Miura, Y. Funakoshi and M. Murakami, *J. Am. Chem. Soc.*, 2014, **136**, 2272; (l) C. Kim, S. Park, D. Eom, B. Seo and P. H. Lee, *Org. Lett.*, 2014, **16**, 1900; (m) S. Rajasekar and P. Anbarasan, *J. Org. Chem.*, 2014, **79**, 8428; (n) R.-Q. Ran, J. He, S.-D. Xiu, K.-B. Wang and C.-Y. Li, *Org. Lett.*, 2014, **16**, 3704.
- X. J. Ma, S. F. Pan, H. X. Wang and W. Z. Chen, *Org. Lett.*, 2014, **16**, 4554.
- (a) H. Shang, Y. Wang, Y. Tian, J. Feng and Y. Tang, *Angew. Chem., Int. Ed.*, 2014, **53**, 5662; (b) E. E. Schultz, V. N. Lindsay and R. Sarpong, *Angew. Chem., Int. Ed.*, 2014, **53**, 9904; (c) S. Kim, J. Mo, J. Kim, T. Ryu and P. H. Lee, *Asian J. Org. Chem.*, 2014, **3**, 926.
- (a) D. J. Lee, H. S. Han, J. H. Shin and E. J. Yoo, *J. Am. Chem. Soc.*, 2014, **136**, 11606; (b) Y. Jiang, X. Y. Tang and M. Shi, *Chem. Commun.*, 2015, **51**, 2122.
- For selected reviews, see: (a) F. Palacios, A. M. O. de Retana, E. M. de Marigorta and J. M. de los Santos, *Eur. J. Org. Chem.*, 2001, 2401; (b) G. S. Singh, M. D'Hooghe and N. De Kimpe, *Chem. Rev.*, 2007, **107**, 2080. For selected examples, see: (c) A. F. Khlebnikov, M. V. Golovkina, M. S. Novikov and D. S. Yufit, *Org. Lett.*, 2012, **14**, 3768; (d) D. A. Candito and M. Lautens, *Org. Lett.*, 2010, **12**, 3312; (e) F. A. F. Khlebnikov, M. S. Novikov and A. A. Amer, *Tetrahedron Lett.*, 2004, **45**, 6003; (f) A. Padwa and T. Stengel, *Tetrahedron Lett.*, 2004, **45**, 5991.
- N. S. Y. Loy, A. Singh, X. X. Xu and C. M. Park, *Angew. Chem., Int. Ed.*, 2013, **52**, 2212.
- (a) J. Feng, Y. H. Wang, Q. G. Li, R. W. Jiang and Y. F. Tang, *Tetrahedron Lett.*, 2014, **55**, 6455; (b) Y. Tian, Y. H. Wang, H. Shang, X. D. Xu and Y. F. Tang, *Org. Biomol. Chem.*, 2015, **13**, 612.
- While this manuscript was under review, several related work were disclosed elsewhere. For references, see: (a) Y. Z. Zhao, H. B. Yang, X. Y. Tang and M. Shi, *Chem. – Eur. J.*, 2015, DOI: 10.1002/chem.201406460; (b) T. Ryu, Y. Baek and P. H. Lee, *J. Org. Chem.*, DOI: 10.1021/acs.joc.5b00036; (c) N. S. Y. Loy, S. Kim and C. M. Park, *Org. Lett.*, 2015, **17**, 395.
- For details of the preparation of the 2*H*-azirines involved in this work, see the ESI†.
- CCDC 1032468 (**3a'**) and 1032469 (**6a**).
- For selected reviews, see: (a) P. G. Baraldi, D. Preti, F. Fruttarolo, M. A. Tabrizi and R. Romagnoli, *Bioorg. Med. Chem.*, 2007, **15**, 17; (b) T. Bando and H. Sugiyama, *Acc. Chem. Res.*, 2006, **39**, 935. For selected examples, see: (c) M. D. Rosa and D. Arnold, *J. Org. Chem.*, 2013, **78**, 8614; (d) A. A. Kanakis and V. Sarli, *Org. Lett.*, 2010, **12**, 4872; (e) C. Dose, M. E. Farkas, D. M. Chenoweth and P. B. Dervan, *J. Am. Chem. Soc.*, 2008, **130**, 6859; (f) K. Schneider, S. Keller, F. E. Wolter, L. Roeglin, W. Beil, O. Seitz, G. Nicholson, C. Bruntner, J. Riedlinger, H.-P. Fiedler and R. D. Süessmuth, *Angew. Chem., Int. Ed.*, 2008, **47**, 3258.
- (a) C. G. Espino, K. W. Fiori, M. Kim and J. Du Bois, *J. Am. Chem. Soc.*, 2004, **126**, 15378; (b) D. N. Zalatan and J. Du Bois, *J. Am. Chem. Soc.*, 2009, **131**, 7558.
- The usage of a nonpolar solvent (toluene) might disfavour path *a* via zwitterionic intermediates. Instead, path *b*-2 via the azatriene intermediate may occur dominantly under this condition. For some relevant references, see: (a) D. A. Colby, R. G. Bergman and J. A. Ellman, *J. Am. Chem. Soc.*, 2008, **130**, 3645; (b) Y. J. Jiang, C.-M. Park and T.-P. Loh, *Org. Lett.*, 2014, **16**, 3432.
- While the exact function of ClCH₂COOH in the reaction remains unclear at this stage, we speculated that it may facilitate path *a* (Scheme 1) by (1) accelerating the ring-expansion of **C** through activation of the imine moiety and (2) promoting the proton-transfer and double bond isomerization.
- While the direct nucleophilic attack of the nitrogen atom of the imine moiety at the C-2 position of azirine could also afford the 1,2-dihydropyrazine products, the observed notable electronic effect at the C-2 position is in agreement with the mechanism *via* carbocation intermediate **F** (path *b*-1).
- Actually, formal [3+3] adducts were obtained with similar substrates in references **14a** and **14b**, indicating that the reaction pathways of the cycloadditions of 1-sulfonyl 1,2,3-triazoles and 2*H*-azirines are very sensitive to the substrates and reaction conditions.